tralokinumab sold brand names adtralza euuk adbry us among others human monoclonal antibody used treatment atopic tralokinumab targets cytokine interleukin common side effects include upper respiratory tract infections colds infections nose throat reactions injection site redness discomfort tralokinumab approved medical use european union united kingdom june approved medical use united states december us food drug administration fda considers firstinclass tralokinumab indicated treatment moderatetosevere atopic dermatitis adults candidates systemic united states tralokinumab indicated treatment moderatetosevere atopic dermatitis adults whose disease adequately controlled topical prescription therapies therapies tralokinumab discovered cambridge antibody technology using protein optimization based ribosome used extensive data sets ribosome display patent protect worldfirst sequenceactivityrelationship clinical development initiated first study completing july medimmune llc initiated phase iib randomized doubleblind study evaluate efficacy tralokinumab adults medimmune astrazeneca started developing tralokinumab asthma phase iii atopic dermatitis phase iib clinical development moderatetosevere ulcerative colitis idiopathic pulmonary fibrosis ipf july year astrazeneca licensed tralokinumab leo pharma skin phase iib study tralokinumab found treatment associated early sustained improvements atopic dermatitis symptoms tralokinumab acceptable safety tolerability profile thereby providing evidence targeting patients atopic june leo pharma announced starting phase iii clinical trials tralokinumab atopic april committee medicinal products human use chmp adopted positive opinion recommending granting marketing authorization medicinal product adtralza intended treatment atopic applicant medicinal product leo pharma tralokinumab approved medical use european union june tralokinumab international nonproprietary name united states adopted name immune activation dostarlimab ibalizumab httpsenwikipediaorgwikitralokinumab